1385-P: Impact of Preanalytical and Analytical Factors on Glucagon and GLP-1 Levels in Humans

Autor: CHRISTINE RASMUSSEN, SASHA KJELDSEN, NICOLE J. JENSEN, NIKLAS HEINZ, BOLETTE HARTMANN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN

Publikováno v: Diabetes. 71

Glucagon and glucagon-like peptide-1 (GLP-1) have important roles in the development and treatment of diabetes. Their plasma concentrations are currently being measured in more than 500 clinical studies according to clinicaltrial.gov. As glucagon and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd1fa2c85cf008468d323bf5334579ba
https://doi.org/10.2337/db22-1385-p

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

Autor: Nicolai J. Wewer Albrechtsen, Andreas Møller, Christoffer Martinussen, Lise L. Gluud, Elias B. Rashu, Michael M. Richter, Peter Plomgaard, Jens P. Goetze, Sasha Kjeldsen, Lasse Holst Hansen, Finn Gustafsson, Carolyn F. Deacon, Jens J. Holst, Sten Madsbad, Kirstine N. Bojsen‐Møller

Publikováno v: Wewer Albrechtsen, N J, Møller, A, Martinussen, C, Gluud, L L, Rashu, E B, Richter, M M, Plomgaard, P, Goetze, J P, Kjeldsen, S, Hansen, L H, Gustafsson, F, Deacon, C F, Holst, J J, Madsbad, S & Bojsen-Møller, K N 2022, ' Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes ', Diabetes, Obesity and Metabolism, vol. 24, no. 10, pp. 2017-2026 . https://doi.org/10.1111/dom.14789

Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post-hoc analysis of a 3-year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba6846d3a03bd775f4f6e599570ac24
https://pubmed.ncbi.nlm.nih.gov/35676803